Mode
Text Size
Log in / Sign up

CYP2D6 allele frequency analysis reveals differential distribution across ancestral subgroups in All of Us Research ProgramYour Ancestry Might Change How Your Meds Work

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note differential CYP2D6 allele frequencies across ancestral subgroups in the All of Us Research Program cohort.

This cohort study utilized data from the National Institute of Health All of Us Research Program Data Browser. The population included the overall cohort and ancestral subgroups comprising East Asian, Middle Eastern, African, and South Asian individuals. The sample size involved 89 CYP2D6 alleles with ClinVar 'drug response' significance and 6,262 CYP2D6 alleles with 'undefined' significance classification.

Analysis of CYP2D6 allele frequencies compared the overall population against ancestral subgroups. In the East Asian ancestry subgroup, 7 of 11 alleles (64%) were more frequent (≥0.10) than in the overall population. No p-values or confidence intervals were reported for these comparisons.

Regarding alleles with 'undefined' significance, 60 of 6,262 alleles showed elevated frequencies (≥0.10) in at least one subgroup. Distribution varied by ancestry: 31/60 in Middle Eastern, 22/60 in African, 21/60 in East Asian, and 4/60 in South Asian. Effect sizes were 52% in Middle Eastern, 37% in African, 35% in East Asian, and 7% in South Asian.

16 of 60 alleles (27%) mapped to 41–76 star allele haplotypes containing at least one sub-allele with 'definitive' allele evidence levels in PharmVar. Safety data including adverse events and tolerability were not reported. Follow-up duration was not reported.

Practice relevance supports potential reclassification of certain 'undefined' alleles and highlights importance of inclusive pharmacogenomic research.

Why Your Family History Matters

Doctors used to assume everyone’s factory worked the same way. But new research shows this is not true for everyone. We used to think one standard dose fit most people. Now we see that ancestry plays a huge role in how genes function.

This matters because millions of people take medicines that depend on this gene. Painkillers, antidepressants, and heart medicines all use this system. When the gene does not match the drug, side effects can happen.

The Surprising Shift in Science

Researchers looked at data from the NIH All of Us Research Program. They checked thousands of people from different ancestral backgrounds. They focused on gene versions that were often labeled as unknown or unclear.

The team found many gene versions were more common in East Asian, African, and Middle Eastern groups. Some were marked as undefined in the past. Many of these showed up often in specific populations.

Think of your genes as keys and your drugs as locks. Some keys fit better than others depending on where your family comes from. This specific gene helps process painkillers, antidepressants, and heart medicines. Small changes in the key shape change the outcome.

About 7 of 11 known drug-response versions were more frequent in East Asians than the overall group. This means standard advice might not fit everyone equally.

What Scientists Did Not Expect

Among 6,262 gene versions marked as undefined, 60 showed high frequency in at least one subgroup. Middle Eastern groups had 31 of these versions. African groups had 22. East Asian groups had 21.

This doesn’t mean your doctor will test you tomorrow.

Experts say we need to include more diverse groups in medical research. This helps ensure everyone gets safe care. The study found 16 of those 60 versions map to star alleles with definitive evidence. This suggests they should be reclassified as important for drug response.

This is not a new pill or a new surgery. It is about better understanding how your body handles medicine. You should talk to your doctor if you have side effects. Do not stop taking your medicine without asking them first.

The study looked at data patterns, not new treatments. Some gene effects are still being confirmed by experts. This is a step toward better data, not a new test in your office.

The Road Ahead for Patients

More studies will likely update how we label these genes. This could lead to better dosing advice in the future. Research takes time to move from data to real-world care. We are building a foundation for safer medicine for everyone.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionCYP2D6 is a highly polymorphic gene with significant pharmacogenomic and public health implications. Understanding the population distribution of CYP2D6 variants offers opportunities to enhance awareness of its pharmacological relevance, particularly across different ancestral groups.MethodsUsing the National Institute of Health All of Us Research Program Data Browser, we identified CYP2D6 alleles with a frequency ≥0.10 in the overall cohort or within ancestral subgroups and classified in ClinVar as having either “drug response” or “undefined” significance. We assessed alleles with frequency differences ≥0.10 between ancestral subgroups and the overall population to highlight subgroup-specific pharmacogenomic relevance. CYP2D6 alleles with ClinVar “undefined” significance classifications were cross-referenced with expert pharmacological resources [e.g., Pharmacogene Variation (PharmVar) Consortium] to identify candidates for reclassification as “drug response” significance variants.ResultsAmong the 89 CYP2D6 alleles with ClinVar “drug response” significance classification, 7 of 11 (64%) were more frequent (≥0.10) in the East Asian ancestry subgroup than in the overall population. Among 6,262 CYP2D6 alleles with “undefined” significance classification, 60 showed elevated frequencies (≥0.10) in at least one subgroup: Middle Eastern (31/60; 52%), African (22/60; 37%), East Asian (21/60; 35%), and South Asian (4/60; 7%) ancestries. Of these 60 alleles, 16 (27%) map to 41–76 star allele haplotypes that contain at least one sub-allele with “definitive” allele evidence levels in PharmVar.ConclusionOur findings highlight the differential distribution and potential pharmacological relevance of CYP2D6 alleles across ancestral subgroups. These insights support potential reclassification of certain “undefined” alleles and highlight the importance of inclusive pharmacogenomic research to improve population-specific drug response knowledge.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.